Manufacturers’ claims in well funded marketing campaigns cannot replace the test of time
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Analysis section. Pharmaceutical Benefits Branch. PBS expenditure and prescriptions January 2000 to December 2000. Available at: www.health.gov.au/pbs/general/pubs/pbbexp/pbdec00/index.htm (accessed Sep 2003).
- 2. Pharmaceutical Benefits Pricing Authority. Annual report for the year ended 30 June 2001. Canberra: AGPS, 2001.
- 3. Kerr SJ, Mant A, Horn FE, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-407.<eMJA full text>
- 4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
- 5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
- 6. Cutts C, LaCase A, Tett S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. Br J Clin Pharmacol 2002; 54: 522-527.
- 7. Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
- 8. Budenholzer BR. Rofecoxib did not provide unequivocal benefit over traditional NSAIDs [letter]. BMJ 2002; 325: 161.
- 9. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in clinical trial of celecoxib [letter]. JAMA 2001; 286: 2398.
- 10. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
- 11. Wooldridge M. Relief for half a million arthritis sufferers [media release]. Canberra: Commonwealth Department of Health and Aged Care; 1 June 2000. Available at www.health.gov.au/mediarel/yr2000/mw/mw20048.htm (accessed Sep 2003).
- 12. Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract 2003; 53: 120-125.
- 13. National Institute for Health Care Management Research and Educational Foundation. Prescription drugs and mass media advertising 2000. Washington: NIHCM Foundation, 2001.
- 14. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust 2002; 177: 291-293. <eMJA full text>
- 15. Health Research Group. New research results on safety of newly approved drugs causes Health Research Group to extend five-year waiting rule to seven years. Worst Pills Best Pills 2002; 8: 41-43.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Australian Prescriber is published by the National Prescribing Service. John Dowden is an unpaid director of Therapeutic Guidelines Ltd, and a member of the Editorial Advisory Board of Australian Medicines Handbook.